Anavex Life Sciences (STU:12X1) EBIT per Share : €-0.49 (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences EBIT per Share?

Anavex Life Sciences's EBIT per Share for the three months ended in Mar. 2024 was €-0.12. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.49.

During the past 3 years, the average EBIT per Share Growth Rate was -9.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -8.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was -9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Anavex Life Sciences's EBIT per Share or its related term are showing as below:

STU:12X1' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -472.3 Med: -9.5 Max: 36.6
Current: -9.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Anavex Life Sciences was 36.60% per year. The lowest was -472.30% per year. And the median was -9.50% per year.

STU:12X1's 3-Year EBIT Growth Rate is ranked worse than
65.93% of 1309 companies
in the Biotechnology industry
Industry Median: 3.6 vs STU:12X1: -9.50

Anavex Life Sciences's EBIT for the three months ended in Mar. 2024 was €-9.61 Mil.

Anavex Life Sciences EBIT per Share Historical Data

The historical data trend for Anavex Life Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences EBIT per Share Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT per Share

Get a 7-Day Free Trial

-0.54

-0.45

-0.46

-0.63

-0.55

Anavex Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.14	-0.13	-0.12	-0.13	-0.12

Anavex Life Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Anavex Life Sciences's EBIT per Share for the fiscal year that ended in Sep. 2023 is calculated as

	EBIT per Share		(A: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-43.602	/	79.788
=	-0.55

Anavex Life Sciences's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.606	/	82.464
=	-0.12

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.49

Anavex Life Sciences (STU:12X1) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Anavex Life Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (STU:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AVXL:USA 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines